title: Papulopustular acneiform eruptions resulting from trastuzumab, a HER2 inhibitor.
authors.affiliation: Harvard Medical School, Boston, MA.
authors.forename: Johanna
authors.initials: J
authors.lastname: Sheu
authors.affiliation: Dermatology Program, Boston Children's Hospital, Boston, MA.
authors.forename: Elena B
authors.initials: EB
authors.lastname: Hawryluk
authors.affiliation: Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.
authors.forename: Georgia
authors.initials: G
authors.lastname: Litsas
authors.affiliation: Harvard Medical School, Boston, MA; Department of Dermatology, Brigham and Women's Hospital, Boston, MA.
authors.forename: Manisha
authors.initials: M
authors.lastname: Thakuria
authors.affiliation: Harvard Medical School, Boston, MA; Department of Dermatology, Brigham and Women's Hospital, Boston, MA; Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA. Electronic address: nleboeuf@partners.org.
authors.forename: Nicole R
authors.initials: NR
authors.lastname: LeBoeuf
mesh_terms: D017486:Acneiform Eruptions / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D000287:Administration, Topical; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D001585:Benzoyl Peroxide / Q000008:administration & dosage; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000473:pathology; D002981:Clindamycin / Q000008:administration & dosage; D003875:Drug Eruptions / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001585:Benzoyl Peroxide; D002981:Clindamycin; D008911:Minocycline; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: Acneiform; Breast cancer; Breast oncology; Cutaneous toxicities; Dermatologic adverse events; EGFR inhibitors